Sipuleucel-T is the first drug for metastatic hormone-resistant prostate cancer that is not cytotoxic or based on hormone-related therapy. Provenge was launched in the US in 2010, and despite ...

Its prostate cancer immunotherapy vaccine Provenge initially promised great ... A further blow came when the UK health watchdog NICE rejected the drug in draft guidance in October, citing the ...

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular ... In contrast to conventional anticancer drugs, the survival advantage observed with sipuleucel-T was not associated ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

Unfortunately, between the immunological vision and the clinical validation lay a drug developers' nightmare. Provenge stuttered and stumbled through the regulatory pipe. Yes, it was relatively ...